share_log

RAPT Therapeutics To Raise $150M in Private Placement to Advance Drug Pipeline

RAPT Therapeutics To Raise $150M in Private Placement to Advance Drug Pipeline

RAPT Therapeutics 將通過定向增發籌集15000萬美元以推進藥物管線。
Benzinga ·  12/23 20:13

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $0.85 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 76,452,000 shares of common stock at a price per pre-funded warrant of $0.8499, for gross proceeds of approximately $150.0 million. The private placement is expected to close on or about December 27, 2024, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, be immediately exercisable and remain exercisable until exercised in full.

RAPT Therapeutics, Inc.(納斯達克:RAPT),是一家臨牀階段的免疫學治療公司,專注於發現、開發和商業化針對炎症疾病中顯著未滿足需求的患者的新療法,今天宣佈已與一組合格投資者簽訂證券購買協議,進行定向增發,包括(i)以每股0.85美元的購買價格發行10,000,000股普通股,以及(ii)向某些投資者提供的預先融資的Warrants,以購買最多76,452,000股普通股,每個預先融資Warrant的價格爲0.8499美元,預計總收益約爲15000萬美元。定向增發預計將在2024年12月27日或之前完成,具體取決於滿足通常的交割條件。預先融資Warrants的行使價格爲每股普通股0.0001美元,可以立即行使,並在完全行使之前保持有效。

The private placement was led by The Column Group and TCGX, with participation by new and existing investors including BVF Partners LP, Deep Track Capital, Foresite Capital, Medicxi, OrbiMed, Perceptive Advisors, Redmile Group and RTW Investments.

此次定向增發由The Column Group和TCGX主導,參與的投資者包括BVF Partners LP、Deep Track Capital、Foresite Capital、Medicxi、OrbiMed、Perceptive Advisors、Redmile Group和RTW Investments等新老投資者。

Net proceeds from the private placement are expected to fund the research and development of the Company's pipeline and for general corporate purposes.

定向增發的淨收入預計將用於公司的研發管道以及一般企業用途。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論